Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether administration of 150 mg clopidogrel is
effective in reducing the one-year incidence of thromboischemic events in patients with high
on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population
overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.